Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Request a sample of customization pricing and purchase options
New Jersey, United States, - The Essential Oils market research report is an in-depth study...